Design of a Phase 3 Randomized, Double-blinded, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults with Ocular Myasthenia Gravis (P1-11.003)

To report the design of a Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of subcutaneous (SC) efgartigimod PH20 (coformulated with recombinant human hyaluronidase PH20), an immunoglobulin G (IgG)1 antibody Fc-fragment that selectively reduces IgG levels by blocking neonatal Fc receptor (FcRn)-mediated IgG recycling, in ocular myasthenia gravis (oMG).